Overview

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)

Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
To assess the safety, tolerability and pharmacokinetics of ABT-199 in female subjects with Systemic Lupus Erythematosus.
Phase:
Phase 1
Details
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Treatments:
Venetoclax